AstraZeneca signs a deal worth up to $247M with US-based Absci Corp. to harness Absci's AI tech for large-scale protein analysis to find a viable cancer therapy (Michael Peel/Financial Times)

December 3, 2023

3

[ad_1]

Michael Peel / Financial Times:

AstraZeneca signs a deal worth up to $247M with US-based Absci Corp. to harness Absci’s AI tech for large-scale protein analysis to find a viable cancer therapy — Deal with Absci is the latest between big pharma and tech companies to build new disease treatments

[ad_2]

Source link

Previous article

FAE strike: other sacrifices to be expected for parents

Next article

in Dubai, a “paradise for influencers” built on black gold, expatriates dream of a more sober life

Latest